#AACR18: Roche spot­lights promis­ing sub­group re­spons­es for lung can­cer com­bo with Tecen­triq

Mer­ck and Bris­tol-My­ers Squibb aren’t the on­ly big play­ers look­ing to make a splash in front­line lung can­cer. Roche is al­so look­ing to el­bow in, and it’s of­fered up a look at some ad­di­tion­al IM­pow­er150 da­ta at AACR to back up their shot.

We al­ready know that Roche ex­ecs gave a pre­lim­i­nary thumbs up for its piv­otal IM­pow­er150 tri­al, study­ing a com­bi­na­tion of Tecen­triq, Avastin and chemo in front­line non­squa­mous non-small cell lung can­cer and hit­ting a haz­ard ra­tio of 0.62 for the full group of pa­tients in the study. Pro­gres­sion Free Sur­vival in the main group was a me­di­an 8.3 months com­pared to 6.8 months in the con­trol, a mar­gin­al gain which isn’t like­ly to stir much ex­cite­ment. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER